glp-1 receptor agonists and cardiovascular outcome trials an update mortality outcomes with vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Kidney and Cardiovascular Outcomes Among
Description
3094 because the medical evidence, injury pattern, and claim criteria may differ
At 52 weeks, weight reduction effects were 7.03 kg, 11.07 kg, and 24.15 kg for mono-agonists, dual-agonists, and tri-agonists, respectively
Acta Pharmacol Sin
17 , 227244 (2021) S
doi: 10.1111/dom.12932 [DOI] [PMC free article] [PubMed] [Google Scholar] 241
